2篇
您的检索式：作者名="Thilo Bluethner"
|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Inhibition of histone deacetylase for the treatment of biliary tract cancer:A new effective pharmacological approach显示文摘瞄准:调查在试管内和在活体内治疗学的效果嘘胆道癌症上的一 deacetylase 禁止者 NVP-LAQ824 和 NVP-LBH589。方法:由 NVP-LAQ824 和 NVP-LBH589 的房间生长抑制是在由 MTT 试金的 7 根人的胆道癌症房间线的学习在试管内。另外, NVP-LBH589 的 anti-tumoral 效果在一个妄想的老鼠模型被学习。Anti-tumoral 药机制被为 MIB-1 为 acH4 和 p21 弄污 WAF-1/CIP-1, PARP 试金,房间周期分析, TUNEL 试金,和 immunhistochemistry 的免疫估计。结果:有两混合物的在试管内治疗显著地压制了所有癌症房间线的生长[吝啬的 IC50 ( 3 d ) 0.11 和 0.05 mumol/L ,分别地],并且与 nucleosomal 的 hyperacetylation 被联系嘘一 H4 , p21 WAF-1/CIP-1 的增加的表示, apoptosis ( PARP 劈开)感应,并且房间周期在 G2/M 逮捕检查点。在 28 d 以后, NVP-LBH589 显著地减少了在 66% 集体的肿瘤(胆汁管癌) 并且 87%( 胆囊癌症) 与安慰剂相比的在活体内,并且加强 gemcitabine 的功效。揭示的肿瘤标本的进一步的分析由 TUNEL 试金增加了 apoptosis 并且减少了房间增长(MIB-1 ) 。结论:我们的调查结果建议 NVP-LBH589 和 NVP-LAQ824 对人的胆道癌症是活跃的在试管内。另外, NVP-LBH589 表明了重要在活体内活动并且加强 gemcitabine 的功效。因此,为胆道癌症的治疗的这新药的进一步临床的评估被推荐。 | Thilo Bluethner Manuel Niederhagen Karel Caca Frederik Serr Helmut Witzigmann Christian Moebius Joachim Mossner Marcus Wiedmann | 2007 | World Journal of Gastroenterology2007，13，35： | 5 |
| 2 | Experimental treatment of pancreatic cancer with two novel histone deacetylase inhibitors显示文摘AIM:To investigate in vitro and in vivo treatment with histone deacetylase inhibitors NVP-LAQ824 and NVP-LBH589 in pancreatic cancer. METHODS:Cell-growth inhibition by NVP-LAQ824 and NVP-LBH589 was studied in vitro in 8 human pancreatic cancer cell lines using the 3-(4,5-dimethylthiazol-2-yl) -2,5-diphenyltetrazolium bromide(MTT) assay. In addition,the anti-tumoral effect of NVP-LBH589 was studied in a chimeric mouse model. Anti-tumoral activity of the drugs was assessed by immunoblotting for p21WAF-1,acH4,cell cycle analysis,TUNEL assay,and immunohistochemistry for MIB-1. RESULTS:In vitro treatment with both compounds significantly suppressed the growth of all cancer cell lines and was associated with hyperacetylation of nucleosomal histone H4,increased expression of p21WAF-1,cell cycle arrest at G2/M-checkpoint,and increased apoptosis. In vivo,NVP-LBH589 alone significantly reduced tumor mass and potentiated the efficacy of gemcitabine. Further analysis of the tumor specimens revealed slightly increased apoptosis and no significant reduction of cell proliferation.CONCLUSION:Our findings suggest that NVP-LBH589 and NVP-LAQ824 are active against human pancreatic cancer,although the precise mechanism of in vivo drug action is not yet completely understood. Therefore,further preclinical and clinical studies for the treatment of pancreatic cancer are recommended. | Martin Haefner Thilo Bluethner Manuel Niederhagen Christian Moebius Christian Wittekind Joachim Mossner Karel Caca Marcus Wiedmann | 2008 | World Journal of Gastroenterology2008，14，23： | 2 |
您所在的机构暂未开通此部分的功能，请联系管理员